Elkington + Fife has unveiled Mark Scott as a new partner in the UK firm’s patent practice.
Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.
The National Health Service, the UK’s government-run health system, has partnered with Gilead Sciences, Merck Sharp and Dohme and AbbVie to help eliminate hepatitis C in England.
AstraZeneca has begun collaborating with UK-headquartered artificial intelligence company BenevolentAI to use AI and machine learning for the discovery and development of new treatments.
The European Union has asked the World Trade Organization to initiate dispute consultations with Turkey over requirements imposed by the country on pharmaceutical products.
European Patent Office president António Campinos will refer a recent decision on the patentability of exclusively obtained by essentially biological processes to the office’s Enlarged Board of Appeal.
The UK Supreme Court’s decision in Actavis v Eli Lilly confirms that a multi-factorial judgement should be used to determine whether an invention is obvious or not, lawyers have told WIPR.
Cancer Research UK has formed a multimillion-pound drug discovery alliance with fellow charity LifeArc and Japanese company Ono Pharmaceutical.
A “biotech boom” is underway in the UK, according to a new report from UK investment management firm Downing.
World Health Organization (WHO) experts have called for central registry on human genome editing research is needed, among a committee consensus that it would be irresponsible for any scientist to conduct gene-editing studies in people.